Health Care & Life Sciences » Pharmaceuticals | Corline Biomedical AB

Corline Biomedical AB | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
2,417.10
2,501.80
5,676.30
5,220.00
7,809.00
Depreciation, Depletion & Amortization
27.10
33.80
28.10
1.00
1.00
Other Funds
70.70
10.40
169.00
28.00
1.00
Funds from Operations
2,460.70
2,478.40
5,817.20
5,247.00
7,809.00
Changes in Working Capital
298.70
159.50
1,586.00
1,964.00
2,831.00
Net Operating Cash Flow
2,759.30
2,318.90
4,231.20
7,211.00
4,978.00
Capital Expenditures
3,084.90
2,718.00
4,844.20
8,536.00
5,020.00
Net Investing Cash Flow
3,084.90
2,718.00
4,844.20
8,537.00
5,020.00
Issuance/Reduction of Debt, Net
5,216.30
5,503.00
1,237.50
-
-
Net Financing Cash Flow
4,683.70
5,503.00
12,298.30
22,744.00
14,990.00
Net Change in Cash
1,160.50
466.00
3,223.00
6,996.00
4,992.00
Free Cash Flow
2,765.80
2,352.40
4,231.20
15,747.00
-
Change in Capital Stock
9,900.00
-
11,060.80
22,744.00
14,990.00
Other Uses
-
-
-
1.00
-

About Corline Biomedical AB

View Profile
Address
Lefflersgatan 5
Uppsala UP 754 50
Sweden
Employees -
Website http://www.corline.se
Updated 09/14/2018
Corline Biomedical AB engages in the research, development, and commercialization of heparin based solutions. Its products intend to improve kidney transplantation, cell therapies, and applications. It operates under the following trademarks: CHC, Renaparin, Cytoparin, and CHS.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.